Strides Pharma Science · NSE: STAR · BSE: 532531

Q4 FY24 results · Jan–Mar 2024

Strides Pharma Science reported revenue from operations of ₹1,084.04 crore (up 9.9% from Q4 FY23) and net profit of ₹10.44 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY24	Q4 FY23	YoY	Q3 FY24	QoQ
Revenue from operations	1,084.04	986.37	+9.9%	1,037.67	+4.5%
Other income	(13.55)	27.12	Turned loss	8.75	Turned loss
Total income	1,070.49	1,013.49	+5.6%	1,046.42	+2.3%
Profit before share of associates & JVs and tax	78.20	33.89	+130.7%	61.99	+26.2%
Share of profit/(loss) of associates & JVs	(48.58)	(40.60)		(51.97)
Net profit for the period	10.44	(13.79)	Turned profit	54.06	−80.7%
Attributable to shareholders of the company	18.18	(9.54)	Turned profit	49.67	−63.4%
EPS, basic (₹)	1.98	(1.06)	Turned profit	5.43	−63.5%
Net margin (%)	1.0	-1.4		5.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY24	Q4 FY23	YoY	Q3 FY24	QoQ
Revenue from operations	617.63	563.56	+9.6%	520.01	+18.8%
Other income	29.63	26.38	+12.3%	8.69	+241.2%
Total income	647.27	589.93	+9.7%	528.70	+22.4%
Profit before tax	52.78	65.20	−19.1%	3.52	15x
Net profit for the period	53.66	62.40	−14.0%	2.54	21x
EPS, basic (₹)	5.84	6.91	−15.5%	0.28	21x
Net margin (%)	8.7	11.1		0.5

Consolidated

Filed with BSE: 23 May 2024, 10:45 IST
Board meeting: 22 May 2024
Period: 01 Jan 2024 to 31 Mar 2024
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 23 May 2024, 10:45 IST
Board meeting: 22 May 2024
Period: 01 Jan 2024 to 31 Mar 2024
Review status: Audited
Source: XBRL filing on BSE